Shown: posts 1 to 2 of 2. This is the beginning of the thread.
Posted by SLS on August 4, 2023, at 21:32:07
FDA Approves zuranolone First Oral Treatment for Postpartum Depression
- Scott
Posted by SLS on August 8, 2023, at 9:35:52
In reply to FDA Approves zuranolone (Zurzuvae), posted by SLS on August 4, 2023, at 21:32:07
> FDA Approves zuranolone First Oral Treatment for Postpartum Depression
>
> https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression
>
>
> - ScottA reminder:
Zuronolone, adminstered orally, is a sister drug to brexanolone, a drug administered via I.V. to treat Postpartum Depression. As of today, zuranolone is FDA approved for treating postpartum depression. However, zuranolone has demonstrated a robust and rapidly-acting antidepressant response in clinical trials for both Major Depressive Disorder (MDD) and Bipolar Depression (BD).
Zuranolone has been observed to begin working within the first week. Also, it can be taken intermittently, although I don't see an advantage in doing this unless it is essential to glean a therapeutic effect.
The property that both zuranolone and brexanolone share, and presumed to be the mechanism of activation is that of a "positive allosteric modulator of GABA-A receptors" (Gamma-Aminobutyric Acid). In other words, zuranolone amplifies GABAergic neurotransmission. GABA generally acts as an inhibitor of excitatory pathways that are innervated by norepinephrine, dopamine, and glutamate. GABA is the main inhibitor to put the "brakes" on these pathways. Glycine fills this role as well.
-----------------------------------------------------------------
"Zuranolone by Sage Therapeutics for Treatment Resistant Depression: Likelihood of Approval"
-----------------------------------------------------------------
- Scott
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD, bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.